Sapience Therapeutics, Inc. Employee Directory
Biotechnology ResearchNew York, United States11-50 Employees
At Sapience, we think boldly about the possibilities for treating cancer. We aim to discover and develop peptide therapeutics to address oncogenic and immunogenic dysregulation that drive cancer. Our pipeline of SPEARs™ (Stabilized Peptides Engineered Against Regulation) disrupt intracellular protein-protein interactions, enabling targeting of transcription factors which have traditionally been considered undruggable. We are advancing our lead programs, ST316, a first-in-class antagonist of β-catenin, and lucicebtide (formerly known as ST101), a first-in-class antagonist of C/EBPβ, through Phase 2 clinical trials. Please engage with us on this platform to learn more!